Last Updated: November 16, 2026

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

Croatia: These 23 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "Croatia: These 23 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can SIRTURO (bedaquiline fumarate) generic drug versions launch in Croatia?

Generic name: bedaquiline fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2026
Generic Entry Controlled by: Croatia Patent P20120639

SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.

See drug price trends for SIRTURO.

The generic ingredient in SIRTURO is bedaquiline fumarate. Additional details are available on the bedaquiline fumarate profile page.

When can OSENI (alogliptin benzoate; pioglitazone hydrochloride) generic drug versions launch in Croatia?

Generic name: alogliptin benzoate; pioglitazone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Croatia Patent P20110094

Drug Price Trends for OSENI
OSENI is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug. There has been litigation on patents covering OSENI

See drug price trends for OSENI.

The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.

When can XENLETA (lefamulin acetate) generic drug versions launch in Croatia?

Generic name: lefamulin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: Croatia Patent P20110869

XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug. There has been litigation on patents covering XENLETA

See drug price trends for XENLETA.

The generic ingredient in XENLETA is lefamulin acetate. Additional details are available on the lefamulin acetate profile page.

When can AMYVID (florbetapir f-18) generic drug versions launch in Croatia?

Generic name: florbetapir f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 26, 2027
Generic Entry Controlled by: Croatia Patent P20120135

AMYVID is a drug marketed by Avid Radiopharms Inc. There are two patents protecting this drug. There has been litigation on patents covering AMYVID

The generic ingredient in AMYVID is florbetapir f-18. Additional details are available on the florbetapir f-18 profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Croatia?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Croatia Patent P20160206

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Croatia?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Croatia Patent P20240595

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Croatia?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Croatia Patent P20250383

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Croatia?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Croatia Patent P20260766

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can TRELSTAR (triptorelin pamoate) generic drug versions launch in Croatia?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Croatia Patent P20181854

TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.

See drug price trends for TRELSTAR.

The generic ingredient in TRELSTAR is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch in Croatia?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Croatia Patent P20181854

TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can XADAGO (safinamide mesylate) generic drug versions launch in Croatia?

Generic name: safinamide mesylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 08, 2027
Generic Entry Controlled by: Croatia Patent P20150136

Drug Price Trends for XADAGO
XADAGO is a drug marketed by Mdd Us. There are three patents protecting this drug. There has been litigation on patents covering XADAGO

See drug price trends for XADAGO.

The generic ingredient in XADAGO is safinamide mesylate. Additional details are available on the safinamide mesylate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in Croatia?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Croatia Patent P20140541

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in Croatia?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Croatia Patent P20190385

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can KYBELLA (deoxycholic acid) generic drug versions launch in Croatia?

Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: Croatia Patent P20150879

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. Additional details are available on the deoxycholic acid profile page.

When can CARDAMYST (etripamil) generic drug versions launch in Croatia?

Generic name: etripamil
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 20, 2027
Generic Entry Controlled by: Croatia Patent P20140801

Drug Price Trends for CARDAMYST
CARDAMYST is a drug marketed by Milestone Pharms Usa. There are six patents protecting this drug. There has been litigation on patents covering CARDAMYST

See drug price trends for CARDAMYST.

The generic ingredient in CARDAMYST is etripamil. Additional details are available on the etripamil profile page.

When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch in Croatia?

Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Croatia Patent P20120661

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. Additional details are available on the tepotinib hydrochloride profile page.

When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch in Croatia?

Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Croatia Patent P20170100

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. Additional details are available on the tepotinib hydrochloride profile page.

When can RASUVO (methotrexate) generic drug versions launch in Croatia?

Generic name: methotrexate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 20, 2027
Generic Entry Controlled by: Croatia Patent P20110148

Drug Price Trends for RASUVO
RASUVO is a drug marketed by Medexus. There is one patent protecting this drug. There has been litigation on patents covering RASUVO

See drug price trends for RASUVO.

The generic ingredient in RASUVO is methotrexate. Additional details are available on the methotrexate profile page.

When can WINLEVI (clascoterone) generic drug versions launch in Croatia?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Croatia Patent P20140421

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are seven patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can WINLEVI (clascoterone) generic drug versions launch in Croatia?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Croatia Patent P20151298

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are seven patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can WINLEVI (clascoterone) generic drug versions launch in Croatia?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Croatia Patent P20191143

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are seven patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can DAKLINZA (daclatasvir dihydrochloride) generic drug versions launch in Croatia?

Generic name: daclatasvir dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 09, 2027
Generic Entry Controlled by: Croatia Patent P20140737

Drug Price Trends for DAKLINZA
DAKLINZA is a drug marketed by Bristol-myers Squibb. There are five patents protecting this drug. There has been litigation on patents covering DAKLINZA

See drug price trends for DAKLINZA.

The generic ingredient in DAKLINZA is daclatasvir dihydrochloride. Additional details are available on the daclatasvir dihydrochloride profile page.

When can PREPOPIK (citric acid; magnesium oxide; sodium picosulfate) generic drug versions launch in Croatia?

Generic name: citric acid; magnesium oxide; sodium picosulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 12, 2027
Generic Entry Controlled by: Croatia Patent P20180215

PREPOPIK is a drug marketed by Ferring Pharms Inc. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering PREPOPIK

See drug price trends for PREPOPIK.

The generic ingredient in PREPOPIK is citric acid; magnesium oxide; sodium picosulfate. Additional details are available on the citric acid; magnesium oxide; sodium picosulfate profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Croatia?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Croatia Patent P20170034

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Croatia?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Croatia Patent P20181837

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Croatia?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Croatia Patent P20220318

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Croatia?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Croatia Patent P20230588

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in Croatia?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2027
Generic Entry Controlled by: Croatia Patent P20141260

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can ZEMDRI (plazomicin sulfate) generic drug versions launch in Croatia?

Generic name: plazomicin sulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 21, 2027
Generic Entry Controlled by: Croatia Patent P20170154

ZEMDRI is a drug marketed by Cipla Usa. There are four patents protecting this drug. There has been litigation on patents covering ZEMDRI

See drug price trends for ZEMDRI.

The generic ingredient in ZEMDRI is plazomicin sulfate. Additional details are available on the plazomicin sulfate profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in Croatia?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Croatia Patent P20140950

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in Croatia?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Croatia Patent P20140950

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch in Croatia?

Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 07, 2027
Generic Entry Controlled by: Croatia Patent P20170241

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty-three patents protecting this drug. There has been litigation on patents covering ORKAMBI

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. Additional details are available on the ivacaftor; lumacaftor profile page.

When can INVEGA SUSTENNA (paliperidone palmitate) generic drug versions launch in Croatia?

Generic name: paliperidone palmitate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 19, 2027
Generic Entry Controlled by: Croatia Patent P20210669

Drug Price Trends for INVEGA SUSTENNA
INVEGA SUSTENNA is a drug marketed by Janssen Pharms. There is one patent protecting this drug and one Paragraph IV challenge. Five tentatively approved generics are ready to enter the market. There has been litigation on patents covering INVEGA SUSTENNA

See drug price trends for INVEGA SUSTENNA.

The generic ingredient in INVEGA SUSTENNA is paliperidone palmitate. Additional details are available on the paliperidone palmitate profile page.

Croatia Branded and Generic Drug Market Assessment: Regulation, Pricing, Patents and Commercial Opportunities

Last updated: October 16, 2026

Croatia is a small but strategically relevant EU pharmaceutical market with a predominantly public reimbursement system, strong generic penetration, centralized price controls and growing demand for specialty medicines. The principal opportunities are generic substitution, biosimilars, hospital medicines, orphan drugs, digital regulatory services and local distribution. The main constraints are low market scale, reimbursement pressure, delayed payment risk, tender concentration, mandatory price reductions and frequent shortages.

What is the size and structure of the Croatian pharmaceutical market?

Croatia’s pharmaceutical market is driven by state-funded reimbursement through the Croatian Health Insurance Fund, Hrvatski zavod za zdravstveno osiguranje, or HZZO. Retail pharmacy sales, hospital procurement and over-the-counter products form the main commercial segments.

Croatia had approximately 3.86 million inhabitants in 2023, with one of the oldest populations in the European Union. The demographic structure supports sustained demand for cardiovascular, oncology, diabetes, respiratory, neurological and immunological medicines (Eurostat, 2024).

Market characteristic Croatia assessment
Population Approximately 3.86 million
Regulatory authority HALMED
Main payer HZZO
EU membership Since July 1, 2013
Currency Euro since January 1, 2023
Core reimbursement channel HZZO positive and complementary lists
Market structure Publicly financed, price-regulated and tender-sensitive
Generic penetration High in reimbursed primary-care categories
Commercial growth areas Oncology, immunology, diabetes, hospital products, biosimilars and specialty care
Key market barrier Small volume base combined with aggressive price competition

The market divides into:

  1. Prescription medicines reimbursed by HZZO.
  2. Hospital medicines purchased through tenders and hospital budgets.
  3. Non-reimbursed prescription products.
  4. OTC medicines and consumer healthcare.
  5. High-cost specialty therapies financed through separate reimbursement mechanisms or hospital budgets.

Domestic production exists, but Croatia is principally a market for imported finished products, regional distributors and multinational pharmaceutical companies. Pliva, part of Teva, is the most prominent Croatian-origin pharmaceutical company and has a major generic and export presence.

How does Croatian pharmaceutical regulation work?

HALMED, the Agency for Medicinal Products and Medical Devices of Croatia, regulates medicinal products, pharmacovigilance, clinical trials, manufacturing, distribution and market surveillance. Croatia operates within the EU pharmaceutical acquis and applies EU marketing authorization rules (HALMED, 2024a).

A company can place a medicine on the Croatian market through four principal routes:

Authorization route Practical use in Croatia
Centralized EU procedure Mandatory or preferred for many innovative, biotechnology and oncology products
Mutual recognition procedure Used where another EU member state has granted the reference authorization
Decentralized procedure Used for products entering Croatia and other EU states simultaneously
National procedure Limited to products marketed only in Croatia

The Croatian authorization holder must maintain local pharmacovigilance, product information, supply and recall capabilities. A local representative or Croatian-language operational infrastructure is often necessary even where the marketing authorization is held elsewhere in the EU.

Medicinal product packaging and patient information must comply with EU serialization and safety-feature requirements. Croatia participates in the European Medicines Verification System, which is relevant to wholesalers, pharmacies and manufacturers.

What is the Croatian reimbursement and pricing system?

HZZO determines whether a medicine is reimbursed and under which conditions. Reimbursed medicines are generally placed on the basic or complementary list. Products on the basic list are reimbursed under the applicable HZZO rules. Complementary-list products may require co-payment or supplementary insurance coverage.

Pricing is a central commercial risk. Croatia uses regulated pricing and external reference mechanisms rather than unrestricted manufacturer pricing. The pricing process typically considers:

  • Prices in reference countries.
  • Comparable medicines and therapeutic alternatives.
  • Generic and biosimilar competition.
  • Reimbursement budget impact.
  • Hospital tender results.
  • Manufacturer applications for inclusion or price adjustment.

Croatia applies European-style generic substitution and reference-pricing principles. Pharmacies and prescribers operate within reimbursement rules that favor lower-cost alternatives where permitted. HZZO may impose reimbursement restrictions based on indication, prescriber specialty, prior authorization or treatment-line status.

Manufacturers must separate three commercial decisions:

  1. Obtaining a marketing authorization.
  2. Securing a reimbursed price.
  3. Winning practical access through prescribing, pharmacy substitution or hospital tenders.

Regulatory approval does not guarantee reimbursement or sales volume.

What patents protect branded drugs in Croatia?

Croatia is covered by the European patent system, including European patents validated in Croatia. Patent protection is generally available for active ingredients, formulations, manufacturing processes, combinations and methods of treatment, subject to European patentability rules.

A Croatian market assessment should review:

IP category Commercial relevance
Compound patent Usually the strongest barrier to generic entry
Salt, polymorph or crystal patent May protect a specific solid form
Formulation patent Relevant to modified release, injectables and delivery systems
Combination patent May protect fixed-dose combinations
Manufacturing-process patent Can restrict production routes but may be difficult to enforce against imported products
Dosage-regimen patent May affect a specific dosing schedule
Use patent Important where the product has multiple indications
SPC Can extend protection for qualifying medicines after patent expiry

Supplementary protection certificates can extend effective protection for a medicinal product after the underlying patent expires. SPC eligibility depends on the basic patent, the relevant marketing authorization and EU regulatory timing rules (European Patent Office, 2024).

Croatia does not have a direct equivalent of the U.S. Orange Book. Companies should instead review:

  • European Patent Register records.
  • Croatian validation and national patent records.
  • SPC registers.
  • EU marketing authorization data.
  • National reimbursement decisions.
  • Litigation and court records.

When do branded medicines lose exclusivity in Croatia?

EU data and market exclusivity generally follow the “8+2+1” framework:

Protection Period
Regulatory data exclusivity 8 years
Market protection 2 additional years
Possible extension for a new indication 1 additional year

The period runs from the initial EU marketing authorization under applicable EU law. Generic applicants can rely on the reference product’s dossier after the data-exclusivity period, but commercial launch remains affected by patents, SPCs, pediatric extensions, orphan exclusivity and national reimbursement conditions (European Commission, 2023).

A generic may obtain authorization before patent expiry but generally cannot lawfully launch while enforceable patent or SPC rights remain in force. Croatia’s practical entry date therefore depends on the earliest effective barrier among:

  • Regulatory exclusivity.
  • Compound patent.
  • SPC.
  • Formulation or process patent.
  • Pediatric extension.
  • Orphan-market exclusivity.
  • Court injunction or settlement restriction.

How do generic drug companies enter Croatia?

Generic entry usually follows the EU regulatory route rather than a Croatian-only strategy. A company may file a decentralized or mutual-recognition application that includes Croatia, or rely on a centralized authorization where required.

The core requirements include:

  • Demonstration of pharmaceutical equivalence.
  • Bioequivalence where applicable.
  • Compliance with good manufacturing practice.
  • A complete quality dossier.
  • Croatian-language product information.
  • Pharmacovigilance and risk-management obligations.
  • Local distribution and supply arrangements.
  • HZZO pricing and reimbursement submission.

The highest-volume generic opportunities are usually mature primary-care products with established prescribing patterns. The most difficult categories are low-priced medicines with several competitors, products requiring cold-chain distribution, sterile injectables and medicines affected by shortages.

Generic manufacturers should model net realized price rather than list price. HZZO reimbursement, pharmacy margins, wholesaler terms, tender discounts, rebates and mandatory price adjustments can materially reduce revenue.

What are the main opportunities for biosimilars in Croatia?

Croatia is an EU biosimilar market governed by the European Medicines Agency and national reimbursement implementation. Biosimilars can compete in oncology, hematology, rheumatology, gastroenterology, endocrinology and supportive care.

The opportunity is strongest where:

  • The reference biologic has lost patent and SPC protection.
  • HZZO has adopted a competitive reimbursement framework.
  • Hospitals use centralized tenders.
  • Physicians accept switching or treatment initiation rules.
  • The product has reliable supply and local medical support.

Biosimilar manufacturers face several risks. Interchangeability and substitution policies may vary by product and national implementation. Hospital procurement can create rapid price erosion. A supplier that wins a tender may need to sustain supply at low margins for an extended contract period.

Biosimilar market entry requires analysis of the reference product’s:

  • European patent and SPC status.
  • Manufacturing and formulation patents.
  • Pediatric extensions.
  • National litigation.
  • Tender history.
  • Clinical guideline position.
  • HZZO reimbursement restrictions.

Are Paragraph IV challenges available in Croatia?

The U.S. Paragraph IV certification system does not apply in Croatia. Croatian and EU generic companies instead assess patent risk through European patent validity, national validation, non-infringement, opposition and revocation mechanisms.

A Croatian launch strategy may involve:

  • European Patent Office opposition.
  • National revocation proceedings.
  • Non-infringement analysis.
  • Patent invalidity defenses.
  • Declaratory litigation.
  • Pre-launch freedom-to-operate opinions.
  • Settlement or license negotiations.

A generic company can obtain marketing authorization before patent expiry, but authorization does not eliminate infringement risk. Early authorization is commercially useful for reimbursement preparation, supply planning and launch readiness, but the launch date must account for enforceable national rights.

What patent litigation affects the Croatian market?

Croatian pharmaceutical litigation is less visible than litigation in larger European jurisdictions. Many disputes are managed through European Patent Office proceedings, German, Dutch, French, Spanish, Italian or UK litigation, followed by coordinated commercial decisions across smaller markets.

The Croatian risk assessment should track:

Litigation issue Croatian impact
EPO opposition Can narrow or revoke a patent relevant to Croatia
National revocation action Can remove Croatian patent protection
Preliminary injunction Can delay local launch
Parallel import dispute Can affect supply and repackaging
SPC challenge Can change the earliest generic entry date
Trademark dispute Can delay product launch or require packaging changes
Patent settlement May limit launch timing or supply rights

Settlement agreements should be reviewed for geographic scope. An agreement covering major EU markets may or may not expressly include Croatia. A license, supply deal or authorized-generic arrangement may create a lawful launch route, but its effect depends on the contract and competition-law analysis.

What is the FDA and EU regulatory status of medicines sold in Croatia?

The FDA has no approval authority over medicines marketed in Croatia. Croatian products must have an EU or Croatian marketing authorization, depending on the authorization route. FDA approval can support development, manufacturing and global regulatory strategy, but it does not replace an EU authorization.

For innovative products, the centralized EMA procedure is often the decisive route. The European Commission grants the authorization, while HALMED supervises national implementation and pharmacovigilance.

Manufacturers should also monitor:

  • EU safety communications.
  • EMA referral procedures.
  • Shortage notifications.
  • GMP inspection findings.
  • Product recalls.
  • Pharmacovigilance signal assessments.
  • Medical-device combination-product requirements.

What regulatory and commercial challenges face pharmaceutical companies?

Pricing and reimbursement pressure

Croatia’s public payer has substantial influence over market access. A product may receive authorization but remain commercially limited if HZZO imposes restrictions, reimbursement conditions or a low reference price.

Small market scale

Croatian volumes rarely support a stand-alone manufacturing or commercial infrastructure for high-cost products. Regional models covering the Adriatic, Central European or Balkan markets are usually more efficient.

Tender concentration

Hospital medicines can be exposed to single-winner or low-price procurement. A tender loss can remove most of a product’s national volume despite a valid marketing authorization.

Product shortages

Shortages create opportunity for reliable suppliers but also increase regulatory and operational scrutiny. Manufacturers must maintain supply continuity and comply with national notification obligations.

Language and packaging requirements

Croatian product information, labeling and safety communications create localization costs. Small-volume products may face disproportionate packaging and batch-release expenses.

Parallel trade

Croatia’s EU membership allows cross-border distribution subject to regulatory and supply-chain rules. Parallel trade can complicate inventory planning and pricing.

How does Croatia compare with larger EU pharmaceutical markets?

Factor Croatia Germany Italy
Market size Small Very large Large
Reimbursement complexity High High High
Tender exposure High in hospitals Moderate to high High
Generic price pressure High High High
Commercial launch economics Often regional Can support national scale Can support national scale
Regulatory framework EU-aligned EU-aligned EU-aligned
Local access driver HZZO reimbursement and tenders Statutory insurance and contracting AIFA, regions and tenders
Strategic role Regional beachhead and compliance market Major revenue market Major volume and tender market

Croatia is more useful as part of a regional launch than as a stand-alone national investment. A company with strong supply reliability, low operating costs and an efficient reimbursement team can compete effectively despite the small market.

What generic launch scenarios exist in Croatia?

Early authorized launch preparation

The company secures EU authorization and prepares HZZO submission before the reference product’s patent or SPC expires. This supports rapid post-expiry launch but does not remove litigation risk.

Day-one launch

The generic launches immediately after the final enforceable barrier expires. This produces maximum market visibility but may trigger aggressive price competition.

Licensed or authorized generic

The originator grants a license or supplies the generic. This reduces patent risk but can limit margin and strategic independence.

Delayed launch

The company waits until litigation or settlement risk declines. This reduces legal exposure but may surrender prescriber relationships and tender access.

Hospital-first launch

The company targets hospital tenders before expanding into retail reimbursement. This is relevant for injectables, oncology medicines and biosimilars.

What licensing opportunities exist in Croatia?

Licensing opportunities are most attractive where the local partner provides:

  • HZZO reimbursement expertise.
  • Hospital tender access.
  • Croatian pharmacovigilance coverage.
  • Wholesaler and pharmacy relationships.
  • GDP-compliant distribution.
  • Shortage-response capacity.
  • Regional regulatory support.

Potential deal structures include:

  • Exclusive Croatian commercialization rights.
  • Non-exclusive distribution.
  • Regional Adriatic licensing.
  • Authorized-generic supply.
  • Biosimilar co-commercialization.
  • Local packaging and release.
  • In-licensing of hospital products.
  • Out-licensing of Croatian-developed generics.

Contract terms should address HZZO price reductions, tender losses, minimum supply obligations, stock-outs, recall costs, pharmacovigilance, parallel trade, termination rights and responsibility for patent disputes.

How strong is the Croatian pharmaceutical patent estate?

The patent estate is legally integrated with the broader European system but commercially fragmented at the national level. Compound patents and SPCs usually provide the strongest protection. Formulation and process patents create narrower barriers and require product-specific analysis.

Patent strength is highest when:

  • The compound patent remains in force.
  • An SPC covers Croatia.
  • The patent has survived EPO opposition.
  • The claim scope is difficult to design around.
  • The product has no viable non-infringing manufacturing route.
  • The originator has a history of enforcing rights.

Patent strength is weaker when:

  • Protection depends only on a narrow formulation claim.
  • The relevant patent has faced successful opposition.
  • Multiple suppliers have design-around routes.
  • The product is subject to established biosimilar competition.
  • The originator relies on untested secondary patents.

Key Takeaways

  • Croatia is an EU-regulated, HZZO-funded pharmaceutical market with high generic and tender pressure.
  • HALMED controls national regulatory implementation, while EMA and the European Commission govern many innovative and biologic products.
  • There is no Croatian Orange Book and no U.S.-style Paragraph IV system.
  • Patent, SPC and regulatory-exclusivity analysis must be performed at the European and Croatian levels.
  • Generic and biosimilar opportunities are strongest in mature reimbursed therapies, hospital medicines and shortage-prone products.
  • HZZO reimbursement is as important as marketing authorization for commercial success.
  • Croatia is generally more attractive as part of a regional strategy than as a stand-alone launch market.
  • Reliable supply, competitive net pricing and local reimbursement expertise are the main commercial advantages.
  • Patent litigation risk often arises from broader European proceedings rather than Croatian cases alone.

FAQs

Is Croatia a good market for generic drug launches?

Yes, particularly for products with established reimbursement, meaningful volume, limited competition and no surviving patent or SPC barrier. Low-priced products with multiple suppliers can be commercially unattractive.

Does Croatia have an Orange Book?

No. Companies should review European patent records, Croatian patent validation data, SPC information, EMA authorization records and national litigation records.

Can a generic be approved in Croatia before the originator patent expires?

It may obtain regulatory approval under applicable EU rules, but commercial launch can still infringe an enforceable patent or SPC. Authorization and launch freedom are separate issues.

How are biosimilars reimbursed in Croatia?

Biosimilars are reimbursed through HZZO and hospital procurement mechanisms, subject to product-specific conditions, tender rules and clinical-use policies.

What is the biggest barrier to pharmaceutical entry in Croatia?

The principal barrier is the combination of low market scale, strict reimbursement pricing, tender competition and supply obligations. Regulatory authorization alone does not ensure market access.

References

  1. European Commission. (2023). The pharmaceutical strategy for Europe and EU medicines legislation. https://health.ec.europa.eu/medicinal-products/pharmaceutical-strategy-europe_en

  2. European Patent Office. (2024). European patent register and supplementary protection certificates. https://www.epo.org/

  3. Eurostat. (2024). Population and demographic developments in Croatia. https://ec.europa.eu/eurostat/

  4. European Medicines Agency. (2024). Biosimilar medicines: Overview and regulatory information. https://www.ema.europa.eu/

  5. HALMED. (2024a). Medicinal products and regulatory procedures. Agency for Medicinal Products and Medical Devices of Croatia. https://www.halmed.hr/

  6. HALMED. (2024b). Shortages, safety monitoring and pharmacovigilance. Agency for Medicinal Products and Medical Devices of Croatia. https://www.halmed.hr/

  7. Hrvatski zavod za zdravstveno osiguranje. (2024). Drug reimbursement lists and prescribing rules. https://hzzo.hr/

  8. OECD. (2023). Health at a glance 2023: OECD indicators. OECD Publishing. https://doi.org/10.1787/7a7afb35-en

More… ↓

⤷  Start Trial

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.